Monthly Archives: April 2013

New Ketamine Data

As was discussed at length in December’s NeuroPerspective, the quest for a rapid-acting anti-depressant (RAAD) continues to be one of the most closely watched races in neuropharmacology. A small but intriguing Mt-Sinai sponsored study comparing ketamine with the anesthetic midazolam … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment

Acadia and the FDA

In the upcoming May issue of NeuroPerspective, we will be including some commentary about institutional and regulatory rituals which endure without clear justification–or at the very least,  deserve some reconsideration. This comes in the wake of having recently had the … Continue reading

Posted in Biotech | Tagged , , , | 1 Comment